Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Treasury Shares (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Treasury Shares readings, the most recent being $481068.0 for Q4 2025.

  • Quarterly Treasury Shares fell 12.12% to $481068.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $481068.0 through Dec 2025, down 12.12% year-over-year, with the annual reading at $481068.0 for FY2025, 12.12% down from the prior year.
  • Treasury Shares hit $481068.0 in Q4 2025 for Terns Pharmaceuticals, down from $529035.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $923693.0 in Q1 2024 and bottomed at $71429.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $415518.8, with a median of $388103.0 recorded in 2023.
  • The largest annual shift saw Treasury Shares soared 418.65% in 2023 before it dropped 29.81% in 2025.
  • Terns Pharmaceuticals' Treasury Shares stood at $71429.0 in 2021, then skyrocketed by 79.59% to $128280.0 in 2022, then soared by 185.23% to $365892.0 in 2023, then soared by 49.62% to $547430.0 in 2024, then decreased by 12.12% to $481068.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Treasury Shares are $481068.0 (Q4 2025), $529035.0 (Q3 2025), and $607760.0 (Q2 2025).